Citations

Clear

1432 citation(s) found for "Uk, Nathan".

Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
Shah, Nirav N. , Jacobson, Caron A. , Johnston, Patrick B. , Abhyankar, Sunil , Isufi, Iris, Ghosh, Monalisa , Ulrickson, Matthew L. , Hardy, Nancy M. , Rapoport, Aaron P. , McKinney, Matthew , Horwitz, Mitchell E. , Lunning, Matthew A. , Denlinger, Nathan , Ancukiewicz, Marek, Nallewar, Madhavi, Coleman, K. C., Eromosele, Esther, Kaleta, Remigiusz, Theruvath, Johanna , Wijatyk, Anna, Maziarz, Richard Thomas , Perales, Miguel‐Angel , Rosenthal, Allison , Muñoz, Javier , Karmali, Reem , Awan, Farrukh T. , Miklos, David B.

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 68-68

10.1182/blood-2024-208539 Get It

Background: Zamto-cel is an investigational autologous tandem CD20-CD19-directed non-cryopreserved CAR-T cell product administered as a fresh formulation to patients (pts) with relapsed/refractory Diffuse Large B Cell Lymphoma (r/r DLBCL) in the DALY II USA clinical trial (NCT04792489), a multicenter, open label, single-arm Phase 2 study. Here, we report efficacy and safety outcomes as part of a pre-planned interim analysis of 59 evaluable patients and 69 patients in the safety population. Methods: Eligible adults had r/r DLBCL after at least 2 prior lines of treatment including anti-CD20 monoclonal antibody and anthracycline-containing regimen and measurable disease per Lugano 2014 classification. Zamto-cel was manufactured utilizing CliniMACS Prodigy® (Miltenyi Biotec), a closed, automated system with a 14-day vein-to-vein time and administered as a fresh formulation. Lymphodepletion chemotherapy was initiated during the manufacturing process (either cyclophosphamide/ fludarabine or bendamustine) prior to receiving a single dose of zamto-cel at a dose of 2.5x106 CAR T cells/kg on Day 0. The primary endpoint was overall response rate (ORR) defined as best overall response (BOR) of either complete response (CR) or partial response (PR). Secondary endpoints included complete response rate (CRR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), safety, and CD19 and CD20 antigen expression at relapse. Results: As of March 29th, 2024, 69 pts received zamto-cel of which 59 were evaluable having received a fresh, conforming product and completed a minimum of 3 months follow-up. Median age was 63 years (range 25-85), 39 (66%) were male. Sixteen pts (27%) received 3 or more lines of prior treatment. The majority of pts (53%) had elevated LDH at study entry, and 49% had ≥ 2 extranodal lesions, indicative of a study population with advanced disease. No pts received any bridging therapy, in the week after apheresis and before lymphodepletion. Only 7 pts (12%) received bendamustine as lymphodepleting regimen. Successful manufacturing of a fresh, in specification product occurred in 91.3% out of 69 treated pts. Four patients received a cryopreserved formulation to permit time for comorbid condition management. The mean viability of the final product was 96.0% with 29.4 % transduction efficacy. No patient died or withdrew during the manufacturing process. The ORR in the evaluable patient population (n=59) as assessed by an Independent Radiology Committee (IRC) was 72.9% (95% CI, 59.7-83.6), with a CRR of 49.2% (95% CI,35.9-62.5). The 6 month and 12 month-PFS was 55% (95%CI, 41-67) and 42% (95%CI, 28-56), respectively; 12 month-OS was 72% (95%CI, 57-83). The median DOR was 11.4 months. All 69 treated pts were assessed for safety outcomes. Treatment-emergent adverse events (TEAEs) were mostly of grade 1-2, the majority of grade ≥ 3 were hematological. Thirty-two pts (46.4%) experienced cytokine release syndrome (CRS), all grade 1-2. Immune effector cell-associated neurotoxicity syndrome (ICANS) was reported in 12 pts (17.4%), grade 1-2 (9 pts; 13.1%); grade 3 (3 pts; 4.3%). One patient experienced immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), which resolved after 2 days. Biopsies at progression were available in 24 pts. CD19-negative relapse (defined as H Score <100) was seen in 2 pts, CD20-negative relapse was observed in 3 pts. Only one patient experienced loss of both antigens compared to pre-treatment status, demonstrating that most lymphomas maintain target antigen expression at relapse after treatment with zamto-cel. Conclusion: This pre-planned interim analysis represents the first pivotal trial of a tandem CD20-CD19 directed non-cryopreserved CAR-T cell product for patients with third-line r/r DLBCL. The trial plans to enroll 100 evaluable patients and the final data will be presented upon study completion. Among the 59 evaluable patients at the interim analysis, there is encouraging activity and a favorable safety profile in DLBCL patients treated with zamto-cel. Unlike currently registered CAR-T cell products, zamto-cel is administered as a fresh product with a short vein-to-vein time of 14 days with lymphodepletion initiated during the manufacturing process. With a manufacturing success rate of 91% we have demonstrated the feasibility of this process among high-risk patients with r/r DLBCL.
Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
McLaughlin, Eric , Lingamaneni, Prasanth , Cao, Miao , Chang, Tiffany , Ganesan, Nivetha, Luu, Binh, Mehta-Shah, Neha, Allen, Pamela B. , Paulino, Darina, Adams, Brittany , Wang, Jie , Feng, Amber , Marchi, Enrica , Gutierrez, Marc , Frosch, Zachary AK , Sklarz, Tammarah , Sethi, Tarsheen , Beaven, Anne , Haverkos, Bradley , Treitman, Rachel, Stevens, Patrick , Mishra, Anjali , Hampel, Paul J. , Brammer, Jonathan E. , Braunstein, Zachary , Barta, Stefan K , Luu, Binh, Mehta–Shah, Neha , Shree, Tanaya , Watkins, Marcus P. , Zain, Jasmine , Roberts, Nathan, Wilcox, Ryan A. , Foss, Francine M. , Stuver, Robert

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 982-982

10.1182/blood-2024-194242 Get It

Introduction: T-PLL is a rare, aggressive malignancy with poor prognosis and limited therapies. Outside of prospective trials utilizing alemtuzumab, data is derived primarily from small retrospective series, and limited data on survival outcomes and therapeutic efficacy, particularly beyond frontline therapy are available. In this large multi-center series, with comprehensive clinical data, we evaluated survival and therapeutic outcomes in T-PLL patients, with a focus on identification of prognostic subgroups of T-PLL, that will inform future investigations into the biology and treatment of this disease. Methods: We retrospectively evaluated all patients diagnosed with T-PLL at 15 academic cancer centers throughout the USA between 2000-2023 using the recent TPLL-ISG staging and response criteria with overall response rate (ORR) defined as CR and PR. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier methods and cox proportional hazard models. Single-cell RNA sequencing (scRNAseq) was performed using the standard 10X Genomics platform. Results: 377 patients, with a median follow-up time of 29 months (range: 0-196) were evaluated. The median age at diagnosis was 64 and 51% were male. In evaluated patients (n=223), TCL1A was positive by cytogenetics or FISH in 82%. 61% of patients had CD4+CD8- T-PLL, 11% of patients had CD4-CD8+ T-PLL, and 24% of patients had CD4+CD8+ T-PLL, with 4% unknown. 175 patients (46.4%) had known nodal involvement at diagnosis identified by PET or CT scan. Among treated patients (n=342, 91%), using TPLL-ISG criteria, the ORR to any frontline treatment was 67% (49% CR, 18% PR). Median OS and PFS was 19 months and 10 months in responding patients from the start of treatment initiation. For those treated with frontline alemtuzumab (n=250), the ORR was 74% (58% CR), with a median OS and PFS of 18 and 12 months. 20 patients (5%) were treated with a combination of alemtuzumab/pentostatin frontline with an ORR of 85% (70% CR), which was superior to alemtuzumab alone (ORR 74%, 58% CR). Patients that had frontline chemotherapy (excluding pentostatin, n=48) had a worse ORR of 35% (15% CR) (p<0.001), and a worse PFS of 4 months (p=0.002), when compared to those who received alemtuzumab. Among patients in 1st CR/PR (n=226), 44% (n=99) received an allograft and had an improved 3-year OS of 50% vs 17%, (HR=0.67, 95%CI 0.48-0.93), and 50% improvement in PFS (HR 0.48, 0.33-0.68) compared to those who did not receive an allograft. For patients that received second line treatment (n=176, 52%), re-treatment with alemtuzumab (n=33) produced a 46% ORR (21% CR). Other active second-line treatments included: pentostatin (n=23; 44% ORR, 17% CR), ruxolitinib-based regimens (n=4; 25% ORR, 0% CR), venetoclax-based regimens (n=13; 39% ORR, 8% CR), bendamustine (n=10; 30% ORR, 0% CR), and nelarabine (n=4; 75% ORR, 50% CR). In subgroup survival analysis, TCL1A+ patients had a worse OS and PFS when compared to TCL1A- patients (23 months vs 43 months; p=0.02), and (14 months vs 24 months; p=0.02) respectively, with HR 1.58 (1.08, 2.31) (p=0.02) for OS and HR 1.62 (1.09-2.40) (p=0.02) for PFS. Furthermore, CD4- T-PLL had worse OS (16 months vs 25 months) when compared to CD4+ patients [HR 1.57 (1.08, 2.27), p=0.02]. Single cell RNA seq in 13 patients, including 3 TCL1A- patients, with a total of 66,269 T-PLL cells, demonstrated a unique RNA signature between the CD4+/- and TCL1A+/- patients, suggesting these represent unique molecular subtypes of T-PLL. Conclusions: In this large, multi-center study of T-PLL, frontline treatment with a combination of alemtuzumab/pentostatin improved response rates and OS. Further, among patients who attained a CR, allograft improved OS & PFS vs no allograft. In relapsed T-PLL, retreatment with alemtuzumab had a high ORR, and we report significant activity of multiple novel/alternative agents with the largest reported numbers to date. Intriguingly, TCL1A+, and CD4- T- PLL had worse OS/PFS, and scRNAseq confirmed unique molecular signatures in these populations, suggesting these represent novel molecular subtypes of T-PLL with prognostic significance. These studies form the foundation for future, targeted, therapeutic studies in this rare, aggressive disease with few treatment options.
Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA)
Chertkow, Howard , Rockwood, Kenneth, Bartha, Robert , Beaudoin, Camille, Bélanger, Nathalie , Bellec, Pierre , Belleville, Sylvie, Bergman, Howard , Best, Sarah, Bherer, Louis , Borrie, Michael, Camicioli, Richard , Chan, Senny , Crowshoe, Lynden , Cynader, Max S., Das, Samir , Dixon, Roger A., Ducharme, Simon , Fahnestock, Margaret , Feldman, Howard , Ferland, Guylaine , Fogarty, Jennifer, Gauthier, Serge, Greenwood, Carol E., Henri-Bellemare, Charlie, Herrmann, Nathan, Itzhak, Inbal, Jacklin, Kristen , Mackenzie, Ian R. , Masellis, Mario, Maxwell, Colleen J. , McLaurin, JoAnne, Mohades, Zia, Montero‐Odasso, Manuel , Morgan, Debra, Nygaard, Haakon B. , O’Connell, Megan E. , Petersen, Ron, Pilon, Randi, Rajah, Maria Natasha, Rapoport, Mark , Roach, Pamela, Robillard, Julie M. , Rylett, R. Jane , Sadavoy, Joel , Seitz, Dallas , Walker, Jennifer , Whitehead, Victor, Wittich, Walter , Feldman, Howard H , Phillips, Natalie A. , Rockwood, Kenneth J. , Anderson, Nicole D. , Andrew, Melissa Kathryn , Bélanger, Nathalie, Belleville, Sylvie , Bethell, Jennifer , Black, Sandra E. , Carrier, Julie C , Cashman, Neil R. , Cuello, A. Claudio , Dang‐Vu, Thien Thanh , Einstein, Gillian , Evans, Alan Charles , Finger, Elizabeth C. , Fisk, John D. , Fon, Edward A , Gan‐Or, Ziv , Hogan, David B. , Hsiung, Ging‐Yuek Robin , Lanctôt, Krista L. , Lim, Andrew S. P. , McAiney, Carrie A. , McGilton, Katherine S. , McLaurin, JoAnne , Mihailidis, Alex , Morgan, Debra, Naglie, Gary , Rajah, Maria Natasha , Rogaeva, Ekaterina A. , Rosa-Neto, Pedro , George‐Hyslop, Peter St , Smith, Eric Edward , Stefanovic, Bojana , Vedel, Isabelle , Wellington, Cheryl L.

Mayo Clinic

Journal of Alzheimer’s Disease | December 5, 2024 | Volume: 102 | Issue: 3 | Pages: 535-561

10.1177/13872877241290990 | PMID 39636028 Get It

The Canadian Consortium on Neurodegeneration in Aging (CCNA) was created by the Canadian federal government through its health research funding agency, the Canadian Institutes for Health Research (CIHR), in 2014, as a response to the G7 initiative to fight dementia. Two five-year funding cycles (2014–2019; 2019–2024) have occurred following peer review, and a third cycle (Phase 3) has just begun. A unique construct was mandated, consisting of 20 national teams in Phase I and 19 teams in Phase II (with research topics spanning from basic to clinical science to health resource systems) along with cross-cutting programs to support them. Responding to the needs of researchers within the CCNA teams, a unique sample of 1173 deeply phenotyped patients with various forms of dementia was accrued and studied over eight years (COMPASS-ND). In the second phase of funding (2019–2024), a national dementia prevention program (CAN-THUMBS UP) was set up. In a short time, this prevention program became a member of the World Wide FINGERS prevention consortium. In this article, the challenges, successes, and impacts of CCNA in Canada and internationally are discussed. Short-term deliverables have occurred, along with considerable promise of impacts in the longer term. The creation of synergy, networking, capacity building, engagement of people with lived experience, and economies of scale have contributed to the considerable success of CCNA by all measures. CCNA is evidence that an organized “centrally-organized” approach to dementia research can catalyze important progress nationally and yield significant and measurable results.
Extracorporeal-CPR Versus Conventional-CPR for Adult Patients in Out of Hospital Cardiac Arrest– Systematic Review and Meta-Analysis
Reddy, Swetha , Garcia, Samuel , Hostetter, Logan , Finch, Alexander S. , Bellolio, Fernanda , Gerberi, Dana , Smischney, Nathan J. , Hostetter, Logan J, Smischney, Nathan J , Bellolio, M Fernanda , Guru, Pramod

Mayo Clinic

Journal of Intensive Care Medicine | December 5, 2024 | Volume: 40 | Issue: 2 | Pages: 207-217

10.1177/08850666241303851 | PMID 39635840 Get It

Objective Extracorporeal cardiopulmonary resuscitation (ECPR) utilizes veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in cardiac arrest patients to reduce the risk of mortality and multiorgan dysfunction from systemic hypoperfusion. We aimed to compare clinical outcomes of patients receiving ECPR versus conventional cardiopulmonary resuscitation (CCPR) for refractory cardiac arrest. Data Sources This was a systematic review and meta-analysis. A librarian searched the main databases, Ovid MEDLINE (including epub ahead of print, in-process & other non-indexed citations), Ovid EMBASE and Ovid Cochrane Central Register of Controlled Trials from inception through July 2024. Study Selection We included randomized controlled trials and observational studies that compared the outcomes of ECPR to CCPR in cardiac arrest patients. Primary outcomes were neurological sequelae and survival. Data Extraction We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Two reviewers independently screened articles, extracted data on selected articles and performed risk of bias assessments using ROBINS-I for non-randomized controlled trials and the revised Cochrane risk of bias tool for randomized controlled trials with disagreements settled by a third independent reviewer. Data Synthesis Out of 3458 studies identified and screened, 28 studies including 304,360 cardiac arrest patients met eligibility criteria and were included. Survival at hospital discharge was 20% for ECPR versus 3.3% for CCPR (OR 0.48 [CI 0.27, 0.84]). Favorable neurological outcome at hospital discharge was 11.8% for ECPR versus 1.9% for CCPR (OR 0.41 [CI 0.17, 1.01]). Complications from bleeding were ten times higher in the ECPR group (35.3% vs 3.7%; OR 0.08 [0.03, 0.24]). Conclusions ECPR appeared to be superior to CCPR for improved neurological outcome and survival in cardiac arrest patients, although bleeding was increased. There was large heterogeneity in the included studies and outcomes reported. Future prospective studies may improve the identification of subgroups of patients that will benefit most from ECPR. Systematic review and meta-analysis registration: PROSPERO - CRD42023394128.
Postradiation Cranial Brachial Plexus Neuropathy: Clinical Examination and Electrophysiologic Diagnosis
Gordon-Hackshaw, Lemuel E., Seven, Nathan A. , Young, Nathan P. , Young, Nathan P , Gordon-Hackshaw, Lemuel E.

Mayo Clinic

Annals of Internal Medicine: Clinical Cases | December 3, 2024 | Volume: 3 | Issue: 12 | Pages: No page available

10.7326/aimcc.2024.0293 Get It

Prothrombotic antibodies targeting the spike protein's receptor-binding domain in severe COVID-19
Zhu, Wen , Zheng, Yongwei , Yu, Mei , Witman, Nathan , Zhou, Lu , Wei, Jianhui, Zhang, Yongguang , Nguyen, Christine , Wang, David , Janecke, Rae , Padmanabhan, Anand , White, Gilbert, Fields, Alexander T. , Kornblith, Lucy Z. , Aster, Richard H. , Zhu, Jieqing , Jobe, Shawn M. , Graham, Mary Beth, Wang, Demin , Wen, Renren , Topchyan, Paytsar , Nguyen, Christine , Wang, David , Janecke, Rae , Padmanabhan, Anand , Baumann Kreuziger, Lisa , Hari, Parameswaran , Gu, Tongjun , Kornblith, Lucy Z , Aster, Richard , Zhu, Jieqing , Cui, Weiguo , Jobe, Shawn , Graham, Mary Beth , Wang, Demin , Wen, Renren , Zhou, Lu , Kreuziger, Lisa Baumann , White, Gilbert C., Hari, Parameswaran , Cui, Weiguo

Mayo Clinic

Blood | November 22, 2024 | Volume: 145 | Issue: 6 | Pages: 635-647

10.1182/blood.2024025010 | PMID 39576992 Get It

Abstract Thromboembolic complication is common in severe coronavirus disease 2019 (COVID-19), leading to an investigation into the presence of prothrombotic antibodies akin to those found in heparin-induced thrombocytopenia (HIT). In a study of samples from 130 hospitalized patients, collected 3.6 days after COVID-19 diagnosis, 80% had immunoglobulin G (IgG) antibodies recognizing complexes of heparin and platelet factor 4 (PF4; PF4/H), and 41% had antibodies inducing PF4-dependent P-selectin expression in CpG oligodeoxynucleotide–treated normal platelets. Unlike HIT, both PF4/H-reactive and platelet-activating antibodies were found in patients with COVID-19 regardless of recent heparin exposure. Notably, PF4/H-reactive IgG antibodies correlated with those targeting the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 spike protein. Moreover, introducing exogenous RBD to or removing RBD-reactive IgG from COVID-19 plasma or IgG purified from COVID-19 plasma significantly reduced their ability to activate platelets. RBD-specific antibodies capable of platelet activation were cloned from peripheral blood B cells of patients with COVID-19. These antibodies possessed sequence motifs in the heavy-chain complementarity-determining region 3 (HCDR3), resembling those identified in pathogenic HIT antibodies. Furthermore, IgG+ B cells having these HCDR3 signatures were markedly expanded in patients with severe COVID-19. Importantly, platelet-activating antibodies present in patients with COVID-19 were associated with a specific elevation of platelet α-granule proteins in the plasma and showed a positive correlation with markers for inflammation and tissue damage, suggesting a functionality of these antibodies in patients. The demonstration of functional and structural similarities between certain RBD-specific antibodies in patients with COVID-19 and pathogenic antibodies typical of HIT suggests a novel mechanism by which RBD-specific antibodies might contribute to thrombosis in COVID-19.
ProtPipe: A Multifunctional Data Analysis Pipeline for Proteomics and Peptidomics
Li, Ziyi , Weller, Cory A. , Shah, Syed Islamuddin , Johnson, Nicholas L. , Hao, Ying , Roberts, Jessica P. , Guha, Deyaan, Bereda, Colleen , Klaisner, Sydney, Machado, Pedro , Zanovello, Matteo , Prudencio, Mercedes , Staff, Nathan P. , Fratta, Pietro , Petrucelli, Leonard , Cookson, Mark , Ward, Michael E. , Singleton, Andrew , Nalls, Mike A. , Fratta, Pietro , Shah, Syed I , Jarreau, Paige B , Roberts, Jessica , Guha, Deyaan , Bereda, Colleen , Klaisner, Sydney , Machado, Pedro M , Zanovello, Matteo , Prudencio, Mercedes , Oskarsson, Björn , Staff, Nathan P , Dickson, Dennis W , Fratta, Pietro , Petrucelli, Leonard , Narayan, Priyanka , Ward, Michael E , Singleton, Andrew B , Nalls, Mike A , Qi, Yue A , Li, Ziyi , Fratta, Pietro , Johnson, Nicholas L , Oskarsson, Björn , Dickson, Dennis W. , Qi, Yue

Mayo Clinic

Genomics, Proteomics & Bioinformatics | November 22, 2024 | Volume: 22 | Issue: 6 | Pages: No page available

10.1093/gpbjnl/qzae083 | PMID 39576693 Get It

Abstract Mass spectrometry (MS) is a technique widely employed for the identification and characterization of proteins, with personalized medicine, systems biology, and biomedical applications. The application of MS-based proteomics advances our understanding of protein function, cellular signaling, and complex biological systems. MS data analysis is a critical process that includes identifying and quantifying proteins and peptides and then exploring their biological functions in downstream analyses. To address the complexities associated with MS data analysis, we developed ProtPipe to streamline and automate the processing and analysis of high-throughput proteomics and peptidomics datasets with DIA-NN preinstalled. The pipeline facilitates data quality control, sample filtering, and normalization, ensuring robust and reliable downstream analyses. ProtPipe provides downstream analyses, including protein and peptide differential abundance identification, pathway enrichment analysis, protein–protein interaction analysis, and major histocompatibility complex (MHC)–peptide binding affinity analysis. ProtPipe generates annotated tables and visualizations by performing statistical post-processing and calculating fold changes between predefined pairwise conditions in an experimental design. It is an open-source, well-documented tool available at https://github.com/NIH-CARD/ProtPipe, with a user-friendly web interface.
Senescence Biomarkers and Trajectories of Frailty and Physical Function After Kidney Transplantation
Lorenz, Elizabeth C. , Smith, Byron H. , Wadei, Hani M. , Mour, Girish , Kennedy, Cassie C. , Schinstock, Carrie A. , Kremers, Walter K. , Cheville, Andrea , Hickson, LaTonya J. , Atkinson, Elizabeth J. , White, Thomas A. , Cheville, Andrea L , Rule, Andrew D , LeBrasseur, Nathan K , Smith, Byron , Hickson, LaTonya J , Schinstock, Carrie , Kennedy, Cassie C , Wadei, Hani M , Kremers, Walter K , Mour, Girish K , Rule, Andrew D. , LeBrasseur, Nathan K.

Mayo Clinic

Clinical Transplantation | November 20, 2024 | Volume: 38 | Issue: 11 | Pages: No page available

10.1111/ctr.70022 | PMID 39564682 Get It

ABSTRACTCellular senescence is a biological mechanism of aging and age‐related diseases. The aim of this study was to examine whether senescence biomarkers are associated with frailty and physical function trajectories in patients undergoing kidney transplantation (KT). We also discussed the relationship between senescence biomarkers and KT function. In this multicenter study, we prospectively assessed plasma levels of senescence biomarkers, frailty as measured by the Physical Frailty Phenotype, and physical function as measured by the Short Physical Performance Battery prior to KT. Frailty, physical function, and KT function were also measured 1 year after KT. Variable associations were assessed using Cox and relaxed least absolute shrinkage and selection operation regression. The cohort consisted of 197 participants (mean age 53 ± 13 years, 61.4% male, and 80.2% White race). Higher pre‐KT levels of macrophage‐derived chemokine (MDC/CCL22) and growth differentiation factor‐15 (GDF‐15) were independently associated with less improvement in frailty and/or physical function during the first year after KT. Higher pre‐KT levels tumor necrosis factor receptor superfamily member 6 (FAS) and MMP‐9 levels were independently associated with lower KT function one year after KT. Pre‐KT cellular senescence may contribute to frailty, physical function, and kidney function trajectories during the first year after KT.
Short-term Surgical Outcomes of Papillary Craniopharyngiomas: A Multicenter Study
Catalino, Michael P. , Pham, D. T. , Pacione, Donato , Suryadevara, Carter M. , Silverstein, Julie , Gardner, Paul A. , Fernandez‐Miranda, Juan C. , Benjamin, Carolina , Kshettry, Varun R. , Zada, Gabriel , Zwagerman, Nathan T. , Cheok, Stephanie , Wu, Kyle C., Little, Andrew S. , Pham, Duy, Rennert, Robert C , Couldwell, William T. , Kim, Won Bae , Kim, Albert , Chicoine, Michael , Barkhoudarian, Garni , Gompel, Jamie J. Van , Palit, Sandhya R. , Prevedello, Daniel M. , Mamelak, Adam N. , Pacult, Mark A. , Karsy, Michael

Mayo Clinic

No container title available | November 13, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5245655/v1 Get It

Abstract Purpose: Craniopharyngiomas are rare parasellar tumors, and papillary craniopharyngiomas (PCP) represent 8-20% of cases. We assessed surgical outcomes of these very rare tumors among patients treated in the last decade. Methods: Retrospective data from the Registry of Adenomas of the Pituitary and Related Disorders (RAPID) were used to evaluate patients with PCP treated between 2011 and 2023 at 14 US-based academic skull base centers. Demographic, imaging, surgical, and outcome variables were analyzed. Results: Ninety-nine patients with PCP were included. Mean age was 51.8±14.7 and 57.6% were male. Most tumors showed mixed cystic/solid components (67.5%), were trans-infundibular (50.0%), and were treated endoscopically (74.5%), with 51.1% demonstrating gross total resection (GTR). Pituitary stalk was preserved in 51.9%. Permanent arginine vasopressin deficiency was seen in 68.8% and was associated with pituitary stalk sacrifice (p=0.02). Cerebrospinal fluid leak was the most common nonendocrine postsurgical, 30-day complication (9.1%), reason for return to the operating room (3.1%), and reason for 90-day readmission (8.1%). Return to the operating room was associated with discharge to a skilled nursing or rehabilitation facility (p=0.0001). Most patients (63.9%) received no adjuvant therapy; GTR was associated with decreased radiotherapy use (p=0.0001). BRAFV600E mutation was detected in 64/69 tumors tested, although only 1 patient was treated with a BRAF inhibitor. Conclusion: To our knowledge, the RAPID consortium enabled the largest real-world clinical information dataset for PCP. Our data can be used as a benchmark for short-term surgical outcomes. Longer-term follow-up studies are needed to understand how to optimize outcomes from each treatment modality.
Pathologic dural invasion is associated with regional recurrence in olfactory neuroblastoma: A multi‐institutional study
Tang, Anthony , Fung, Nicholas , Champagne, Pierre‐Olivier , Fernandez‐Miranda, Juan C. , Gardner, Paul , Hwang, Peter H. , Nayak, Jayakar V. , Patel, Chirag , Patel, Zara M. , Celda, María Peris, Sanusi, Olabisi , Thorp, Brian D. , Zenonos, Georgios A. , Zwagerman, Nathan T. , Nayak, Jayakar V , Patel, Zara , Pinheiro-Neto, Carlos, Snyderman, Carl H , Wang, Eric W , Choby, Garret , Hwang, Peter H , Taori, Suchet , Fung, Nicholas, Almeida, João Paulo , Pinheiro‐Neto, Carlos , Gompel, Jamie J. Van , Geltzeiler, Mathew , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | November 13, 2024 | Volume: 15 | Issue: 4 | Pages: 373-383

10.1002/alr.23489 | PMID 39535364 Get It

AbstractObjectiveNeck metastases are a poor prognostic factor in olfactory neuroblastoma (ONB). Pathologic dural invasion (pathDI) may increase the risk of neck metastases due to invasion of dural lymphatics. We aim to evaluate the prognostic value of pathDI in predicting rates of neck metastases and recurrence using a large, multicenter database of ONB patients.Data sourcesRetrospective review of a prospective, multicenter database of electronic health records of all patients who presented with ONB between 2005 and 2021 at nine tertiary academic care centers within North America.Review methodsClinicopathologic features including modified Kadish staging systems, margin status, treatment modalities, Hyams grading, follow‐up time, and survival.ResultsOf 258 ONB patients, 189 patients met the inclusion criteria. The 10‐year neck recurrence‐free survival (neck‐RFS) rates were 85.7% (75.6‒97.3) and 61.8% (47.9‒79.8) for patients without and with pathDI, respectively (p = 0.018). Time‐to‐event multivariable regression analysis found pathDI to have an odds ratios of 9.7 (95% confidence interval [CI] 1.2–80.4, p = 0.04) for neck‐RFS and 9.5 for RFS at any site (95% CI 1.1–83.3, p = 0.04).ConclusionIn multivariable analysis, the presence of pathDI appears to be the strongest predictor of neck recurrence and recurrence at any site. Future studies exploring the benefit of elective neck dissection or radiation for patients with pathDI may impact disease management.